Sentinel Oncology

Welcome

  • Sentinel Oncology is a small molecule drug discovery company focusing on the discovery and development of new chemical entities for the treatment of cancer.
  • Sentinel Oncology is seeking partners to out-license products from its oncology pipeline at the pre-clinical development phase.
  • The company was founded in 2005 and is located on the Cambridge Science Park, Cambridge, UK

Recent News

January 2008

Sentinel Oncology announce S144, a pre-clinical candidate molecule from the Checkpoint kinase 1 inhibitor programme is available for licensing. S144 is a highly selective CHK1 kinase inhibitor and displays excellent in-vivo efficacy. To arrange a discussion click HERE.

October 2007

Sentinel Oncology are delighted to announce receipt of a £1.3m grant from the Wellcome Trust as part of their Seeding Drug Discovery initiative to fund their novel anti-cancer drug discovery activities. A full press release can be found HERE